ICML 2019 | Polatuzumab/obinutuzumab/lenalidomide for R/R follicular lymphoma

Catherine Diefenbach

Catherine Diefenbach, MD, NYU Langone, New York, NY, discusses the interim analysis of the Phase Ib/II study of polatuzumab vedotin, obinituzumab and lenalidomide for relapsed/refractory follicular lymphoma (NCT02600897). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  
Similar topics